Effect of amifostine in head and neck cancer patients treated with radiotherapy: a systematic review and meta-analysis based on randomized controlled trials

Amifostine is the most clinical used chemical radioprotector, but its effect in patients treated with radiation is not consistent. By searching Medline, CENTRAL, EMBASE, ASCO, ESMO, and CNKI databases, the published randomized controlled trials (RCTs) about the efficacy of amifostine in HNSCC patien...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2014-05, Vol.9 (5), p.e95968
Hauptverfasser:	Gu, Jundong, Zhu, Siwei, Li, Xuebing, Wu, Hua, Li, Yang, Hua, Feng
Format:	Artikel
Sprache:	eng
Schlagworte:	Amifostine Amifostine - pharmacology Amifostine - therapeutic use Analysis Anemia Cancer Cancer patients Cancer therapies Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - radiotherapy Care and treatment Chemoradiotherapy Clinical trials Combined Modality Therapy Confidence intervals Data processing Dysphagia Handbooks Head & neck cancer Head and neck cancer Head and Neck Neoplasms - drug therapy Head and Neck Neoplasms - radiotherapy Hematology Humans Hypotension Laboratories Leukopenia Lung cancer Medicine and Health Sciences Meta-analysis Metastasis Mucositis Nausea Oncology Patients Radiation Radiation Injuries - prevention & control Radiation therapy Radiotherapy Randomization Randomized Controlled Trials as Topic - methods Researchers Side effects Squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck Statistical analysis Studies Systematic review Thrombocytopenia Toxicity Vomiting Xerostomia
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Amifostine is the most clinical used chemical radioprotector, but its effect in patients treated with radiation is not consistent. By searching Medline, CENTRAL, EMBASE, ASCO, ESMO, and CNKI databases, the published randomized controlled trials (RCTs) about the efficacy of amifostine in HNSCC patients treated with radiotherapy were collected. The pooled efficacy and side effects of this drug were calculated by RevMan software. Seventeen trials including a total of 1167 patients (604 and 563 each arm) were analyzed in the meta-analysis. The pooled data showed that the use of amifostine significantly reduce the risk of developing Grade 3-4 mucositis (relative risk [RR],0.72; 95% confidence interval [CI],0.54-0.95; p
ISSN:	1932-6203 1932-6203
DOI:	10.1371/journal.pone.0095968